Candel Therapeutics, Inc. (CADL)
Nasdaq · Healthcare · Biotechnology
$10.23+0.49%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $783M
- 52-week range
- $4.35 – $14.00
- 52-week change
- +86.11%
- EPS (trailing)
- −$1.47
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$38.2M
- Diluted EPS
- −$0.72
- Free cash flow
- −$38.9M
From the company’s annual report on SEC EDGAR.
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Headquarters: Needham, United States · 55 employees · candeltx.com